Topic: patent expirations
Ciprodex is one of several first-to-file or first-to-market generics Endo aims to launch in the coming years.
Each year, drugmakers lose their monopolies on a slate of big-selling old medicines. While top brands like Lyrica and Herceptin lost exclusivity last year—and more big rollouts are expected for 2021 and beyond—this year's exclusivity losses will cause some significant pain of their own.
Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.